ArticleFrontiers in oncology2026
Case Report: Re-irradiation of out-of-field recurrence of malignant phyllodes tumors of the breast after adjuvant radiotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Phyllodes tumor of the breast (PTB) is a rare fibroepithelial neoplasm, classified as benign, borderline, and malignant. They typically present as solitary, painless, firm masses with potential rapid enlargement, and 20% exceed 10 cm, often indicating malignancy. Local recurrence frequently occurs within two years postoperatively. While the survival benefit of adjuvant radiotherapy remains controversial, it significantly reduces recurrence rates. We report a 27×14 cm malignant PTB and evaluate optimal radiotherapy strategies and re-irradiation safety in recurrent cases. Case report: A 55-year-old female presented with a rapidly enlarging left breast mass, initially detected seven years prior, measuring 50×40 cm on physical examination. The patient underwent complete surgical excision, with a postoperative pathological mass measuring 27×14 cm, followed by adjuvant radiotherapy (50 Gy/25 fractions). One month after radiation, a 15×15 cm axillary recurrence was resected (10×8 cm specimen). Two months later, a 10×8 cm infraclavicular recurrence was excised (6×5 cm specimen). Subsequently, six cycles of epirubicin-cyclophosphamide chemotherapy and re-irradiation (45-60 Gy/25 fractions) were administered. At present, there is no evidence of local recurrence. Conclusions: This case highlights the potential role of adjuvant RT in reducing recurrence and the feasibility of carefully selected re-irradiation for recurrent MPTs. Prospective studies are needed to define optimal target volume of radiotherapy, dose fractionation, and the safety of re-irradiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.